Serum albumin level predicts survival of patients with gastrointestinal acute graft-versus-host disease after allogeneic stem cell transplantation

Annals of Hematology

Volumn 93, Issue 5, 2014, Pages 855-861

  Ayuk, Francis ^a   Bussmann, Lara ^a   Zabelina, Tatjana ^a   Veit, Ronja ^a   Alchalby, Haefaa ^a   Wolschke, Christine ^a   Lellek, Heinrich ^a   Bacher, Ulrike ^a   Zander, Axel R ^a   Kröger, Nicolaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Gut acute GVHD; Serum albumin

Indexed keywords

ALBUMIN; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; FLUDARABINE; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY; TREOSULFAN;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ADULT; AGED; ALBUMIN BLOOD LEVEL; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC MYELOID LEUKEMIA; DISEASE MARKER; FEMALE; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; WHOLE BODY RADIATION;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; FEMALE; GASTROINTESTINAL TRACT; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYELOABLATIVE AGONISTS; PROGNOSIS; RETROSPECTIVE STUDIES; SERUM ALBUMIN; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84898855168     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-013-1957-0     Document Type: Article

References (30)

1. Martin PJ, Schoch G, Fisher L et al (1990) A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 76(8):1464-1472, Oct 15
2. MacMillan ML, Weisdorf DJ, Wagner JE et al (2002) Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant 8(7):387-394
3. Arai S, Margolis J, Zahurak M, Anders V, Vogelsang GB (2002) Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant 8(3):155-160
4. Xhaard A, Rocha V, Bueno B et al (2012) Steroid-refractory acute GVHD: lack of long-term improved survival using new generation anticytokine treatment. Biol Blood Marrow Transplant 18(3):406-413
5. Sormani MP, Oneto R, Bruno B et al (2003) A revised day +7 predictive score for transplant-related mortality: serum cholinesterase, total protein, blood urea nitrogen, gamma glutamyl transferase, donor type and cell dose. Bone Marrow Transplant 32(2):205-211
6. Lunn RA, Sumar N, Bansal AS, Treleaven J (2005) Cytokine profiles in stem cell transplantation: possible use as a predictor of graft-versus-host disease. Hematology 10:107-114
7. Choi SW, Kitko CL, Braun T et al (2008) Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. Blood 112:1539-1542
8. Fuji S, Kim SW, Fukuda T et al (2008) Preengraftment serum C-reactive protein (CRP) value may predict acute graft-versus host disease and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 14:510-517
9. Ferrara JL, Harris AC, Greenson JK et al (2011) Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood 118(25):6702-6708
10. Weisdorf SA, Salati M, Longsdorf JA, Ramsay NKC, Sharp HL (1983) Graft-versus-host disease of the intestine: a protein losing enteropathy characterized by fecal α antitrypsin. Gastroenterology 85:1076-1081
11. Rodriguez-Otero P, Porcher R, Peffault De Latour R et al (2012) Fecal calprotectin and alpha-1 antitrypsin predict severity and response to corticosteroids in gastrointestinal graft-versus-host disease. Blood 119(24):5909-5917
12. Hagen LE, Schechter T, Luk Y, Brodovitch A, Gassas A, Doyle JJ (2011) High alpha-1 antitrypsin clearance predicts severity of gut graft-versus-host disease (GVHD) in childrenPediatr. Transplant 15(6):659-663
13. Srinivasan R, Daniels J, Fusaro V et al (2006) Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis. Exp Hematol 34:796-801
14. Weissinger EM, Schiffer E, Hertenstein B et al (2007) Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 109(12):5511-5519
15. Paczesny S, Krijanovski OI, Braun TM et al (2009) A biomarker panel for acute graft-versus-host disease. Blood 113:273-278
16. Goussetis E, Paisiou A, Kitra V et al (2011) Acute gastrointestinal graft-versus-host disease in pediatric patients: serum albumin on day 5 from initiation of therapy correlates with nonrelapse mortality and overall survival. Biol Blood Marrow Transplant 17(7):1058-1066
17. Rezvani AR, Storer BE, Storb RF et al (2011) Decreased serum albumin as a biomarker for severe acute graft-versus-host disease after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 17(11):1594-1601
18. Helmberg W, Lanzer G, Zahn R, Weinmayr B, Wagner T, Albert E (1998) Virtual DNA analysis - a new tool for combination and standardised evaluation of SSO, SSP and sequencing-based typing results. Tissue Antigens 51(6):587-592
19. Marsh SG, Albert ED, Bodmer WF et al (2002) Nomenclature for factors of the HLA system, 2002. Tissue Antigens 60(5):407-464
20. Robinson J, Walter MJ, Parham P et al (2003) IMGT/HLA and IMGT/MHC: sequence database for the study of the major histocompatibility complex. Nucleic Acids Res 31:311-314
21. Schmid C, Schleuning M, Hentrich M et al (2008) High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission. Bone Marrow Transplant 41(8):721-727
22. Przepiorka D, Weisdorf D, Martin P et al (1995) 1994 Concensus conference on acute GVHD grading. Bone Marrow Transplant 15:825-828
23. Harrell F, Lee K (1986) Verifying assumptions of the proportional hazards model. Proc 11th Annual SAS. User's Group Int 11:823-828
24. Gooley TA, Chien JW, Pergam SA et al (2010) Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 363:2091-2101
25. Lee KH, Choi SJ, Lee JH et al (2005) Prognostic factors identifiable at the time of onset of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. Haematologica 90(7):939-948
26. Finke J, Bethge WA, Schmoor C et al (2009) Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 10(9):855-864
27. Bacigalupo A, Lamparelli T, Milone G et al (2010) Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day + 7 after alternative donor transplants. Bone Marrow Transplant 45(2):385-391
28. Don BR, Kaysen G (2004) Serum albumin: relationship to inflammation and nutrition. Semin Dial 17:432-437
29. Levine JE, Huber E, Hammer ST et al (2013) Low Paneth cell numbers at onset of gastrointestinal graft-versus-host disease identify patients at high risk for nonrelapse mortality. Blood 122(8):1505-1509
30. Harris AC, Ferrara JL, Braun TM et al (2012) Plasma biomarkers of lower gastrointestinal and liver acute GVHD. Blood 119(12):2960-2963